急性偏頭痛治療の世界市場

急性偏頭痛治療の世界市場は2030年までに94億米ドルに到達

2024年に40億米ドルと推定される急性偏頭痛治療の世界市場は、2024～2030年の分析期間においてCAGR 15.3%で成長し、2030年には94億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるトリプタン製剤は、CAGR17.2%を記録し、分析期間終了時には30億米ドルに達すると予測されます。CAGR拮抗薬セグメントは、分析期間中のCAGR成長率が13.0%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 20.5％で成長予測

米国の急性偏頭痛治療市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは20.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.1%と13.8%と予測されています。欧州では、ドイツがCAGR約12.2%で成長すると予測されています。

世界の急性偏頭痛治療市場- 主要動向と促進要因のまとめ

急性偏頭痛治療は増加する患者集団のニーズに対応するためにどのように進化しているか？

臨床医、研究者、製薬企業が、この衰弱性神経疾患に苦しむ患者の増大するニーズに対応しようと努力しているため、急性片頭痛の治療状況は大きく変化しています。ズキズキする痛み、吐き気、羞明、幻聴を特徴とする急性片頭痛発作は、日常生活機能と生活の質を著しく損なう。従来の治療では、非ステロイド性抗炎症薬（NSAIDs）などの非特異的鎮痛薬や、1990年代にゴールドスタンダードとなったセロトニン受容体作動薬の一種であるトリプタン系抗炎症薬に頼ることが多くなりました。これらの薬剤は多くの患者にとって緩和をもたらしたが、すべての患者、特に血管収縮薬を安全に使用できない心血管系の合併症を持つ患者にとって、有効でも忍容性があるわけでもないです。ゲパンツ（CGRP受容体拮抗薬）やダイタン（セロトニン5-HT1F受容体作動薬）のような新しいクラスの薬剤の出現は、片頭痛の根本的な病態生理学を標的とする上で、重要な飛躍を意味します。これらの薬剤は、旧来の治療に伴う心血管系のリスクを伴わずに有効性を示し、より幅広い患者に使用することができます。経口薬に加え、点鼻薬、注射薬、急速に溶ける錠剤が導入され、より迅速な緩和と簡便な投与が可能となっています。このような治療法の進化は、迅速な発症、副作用の軽減、忍容性の向上を重視した患者中心の治療へのシフトを反映しています。片頭痛が公衆衛生に与える影響に対する認識が高まるにつれ、ヘルスケアプロバイダーと患者の双方が早期かつ効果的な介入を提唱するようになり、急性期治療の分野における研究と革新が推進されています。

なぜ新薬クラス別が急性偏頭痛治療市場で勢いを増しているのか？

薬剤クラス別新薬が急性偏頭痛治療市場で勢いを増しているのは、片頭痛発作に関与する生化学的プロセスを標的とした作用機序を提供するためです。最近の最も重要な動向の一つは、ゲパントとして知られるCGRP（カルシトニン遺伝子関連ペプチド）受容体拮抗薬の開発です。CGRPは、脳血管の炎症と血管拡張を促進することにより、片頭痛の発症に極めて重要な役割を果たすと考えられている神経ペプチドです。ウブロゲパントやリメゲパントなどのゲパントは数カ国で承認されており、心血管系の危険因子を有する患者にも安全な非血管収縮性の選択肢を提供しています。同様に、ラスミジタンのようなジタンは、セロトニン5-HT1F受容体に作用し、血管収縮を起こすことなく片頭痛に関連した痛みのシグナル伝達を阻害します。このような新しい治療法は臨床医にとって魅力的です。というのも、作用発現の遅れ、薬剤の使い過ぎによる頭痛、脆弱な集団における禁忌など、従来の治療に伴う限界を回避しながら、急性の緩和をもたらすからです。さらに、ドラッグデリバリーシステムの進歩により、バイオアベイラビリティと患者のアドヒアランスが向上しています。経鼻スプレーや経口溶解錠のような製剤は、錠剤を飲み込むことが困難な片頭痛の活動中に、より速く吸収され、投与が容易になります。臨床試験では、これらの新しい治療法は忍容性が高く、消化器系の副作用が少なく、薬の使い過ぎのリスクが低いことも示されています。規制当局の承認が拡大し、安全性と有効性を裏付ける実臨床データが得られたことで、これらの新しい治療薬は急性片頭痛の管理方法を変え、世界中で治療ガイドラインの再評価を促しています。

個々の患者に合わせた急性片頭痛治療を行う上で、臨床医が考慮すべき重要な点は何か？

急性偏頭痛治療を管理する臨床医は、治療法を調整する際に有効性、忍容性、併存疾患、患者の嗜好のバランスをとる必要があり、この領域では個別化治療がますます重要になっています。従来のトリプタン系薬剤は血管収縮作用があるため、脳卒中、心臓病、コントロールされていない高血圧の既往歴のある患者には禁忌です。このような患者には、ゲパンツやダイタンのような新しい選択肢がより安全な選択肢となります。もう1つの要因は、片頭痛発作の頻度と強さです。片頭痛発作の頻度が低い患者にはNSAIDsやトリプタン系薬剤がよく効くが、頻度が高い患者や治療抵抗性の片頭痛患者には次世代薬剤や併用療法が必要になります。臨床医は治療開始のタイミングも考慮しなければならないです。片頭痛の軽い段階での早期介入は、痛みが増悪してから遅らせる治療よりも一般的に有効だからです。薬剤の投与方法も重要な検討事項です。利便性から経口錠剤を好む患者もいれば、発作時に吐き気や嘔吐を伴う場合は、点鼻薬や注射薬など経口以外の選択肢を必要とする患者もいます。副作用プロファイル、薬物間相互作用の可能性、使いやすさはすべて、アドヒアランスと患者全体の満足度に影響します。さらに、患者の治療歴や薬の使い過ぎによる頭痛の既往歴を把握することは、症状を悪化させないために不可欠です。多様な治療オプションが利用できるようになったことで、臨床医は転帰を最適化し、患者体験を向上させるような個別化戦略を立案できるようになりました。共同意思決定が標準的な治療になるにつれ、患者が治療法の選択に参加することは、片頭痛発作の急性期治療を長期的に成功させるために不可欠です。

世界の急性偏頭痛治療市場の成長を促進する要因とは？

急性偏頭痛治療市場の世界の成長は、片頭痛治療へのアプローチを再構築している疫学的、技術的、規制的、消費者重視の要因の組み合わせによって牽引されています。まず第一に、世界中で片頭痛の有病率が高く、推定10億人が罹患していることから、より良く、より早く症状を緩和することを求め続ける、広大で十分な治療を受けていない患者層が確立されています。片頭痛が深刻で障害を伴う神経疾患であるという認識が高まるにつれ、ヘルスケアシステムは診断と治療に多くの資源を投入するようになっています。多くの国で健康保険が適用されるようになり、片頭痛治療薬が国の処方箋に含まれるようになったことで、従来の治療薬と革新的な治療薬の両方に対する患者のアクセスも向上しています。技術面では、製薬会社は分子生物学や神経科学の進歩を活用し、CGRPやセロトニンのサブタイプなど、片頭痛発作に関与する特定の経路を標的とする、より精密な薬剤を開発しています。FDAやEMAなどの規制機関は、ファストトラックやブレークスルー指定などのメカニズムを通じて承認を迅速化することで、片頭痛患者のアンメットニーズに応えています。これにより開発期間が短縮され、新しい治療薬がより迅速に市場に投入されるようになりました。副作用が少なく、即効性があり、安全性のプロファイルが広い治療に対する患者の要求は、医薬品の研究開発の優先順位に影響を与え、製品の差別化を促進しています。さらに、デジタルヘルスプラットフォームや片頭痛追跡アプリの成長により、より優れたデータ収集と疾病管理が可能になり、より個別化された、より迅速な治療アプローチが育まれています。患者擁護団体や専門家協会による教育活動も、世界の治療水準を引き上げています。これらの力を総合すると、急性偏頭痛治療市場の拡大に拍車がかかるだけでなく、片頭痛治療がよりアクセスしやすく、効果的で、患者一人ひとりのニーズに沿ったものとなる未来への道も開かれつつあります。

セグメント

薬剤タイプ（トリプタン系薬剤、CGRP拮抗薬、非ステロイド性抗炎症薬、β-アドレナリン遮断薬、エルゴアルカロイド系薬剤、その他の薬剤タイプ）、投与経路（経口投与、注射投与、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

• AbbVie Inc.
• Agenus Inc.
• Amgen Inc.
• AstraZeneca plc
• Biohaven Ltd.
• CoLucid Pharmaceuticals Inc.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Endo International plc
• GlaxoSmithKline plc（GSK）
• H. Lundbeck A/S
• Impel Pharmaceuticals Inc.
• Johnson & Johnson（Janssen）
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries
• Tonix Pharmaceuticals
• Zosano Pharma Corporation

AIインテグレーション

当社は、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Acute Migraine Treatment Market to Reach US$9.4 Billion by 2030

The global market for Acute Migraine Treatment estimated at US$4.0 Billion in the year 2024, is expected to reach US$9.4 Billion by 2030, growing at a CAGR of 15.3% over the analysis period 2024-2030. Triptans Drug, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the CGRP Antagonist Drug segment is estimated at 13.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 20.5% CAGR

The Acute Migraine Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 20.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Acute Migraine Treatment Market - Key Trends & Drivers Summarized

How Is Acute Migraine Treatment Evolving to Address the Needs of a Growing Patient Population?

The treatment landscape for acute migraine is undergoing significant transformation as clinicians, researchers, and pharmaceutical companies strive to address the growing needs of patients who suffer from this debilitating neurological disorder. Acute migraine attacks, characterized by throbbing pain, nausea, photophobia, and phonophobia, can severely impair daily functioning and quality of life. Traditionally, treatments have relied heavily on non-specific pain relievers such as NSAIDs, and triptans, a class of serotonin receptor agonists that became the gold standard in the 1990s. While these drugs have provided relief for many, they are not effective or tolerable for all patients, especially those with cardiovascular comorbidities who cannot safely use vasoconstrictive medications. The emergence of newer classes of medications such as gepants (CGRP receptor antagonists) and ditans (serotonin 5-HT1F receptor agonists) represents a critical leap forward in targeting the underlying pathophysiology of migraines. These drugs offer efficacy without the cardiovascular risks associated with older treatments and can be used in a broader range of patients. In addition to oral medications, nasal sprays, injectables, and rapidly dissolving tablets are being introduced to offer faster relief and more convenient administration. This evolution in treatment modalities reflects a shift toward patient-centric care, emphasizing rapid onset, reduced side effects, and improved tolerability. As awareness of migraine’s impact on public health increases, both healthcare providers and patients are advocating for early and effective intervention, which is propelling research and innovation in the acute treatment space.

Why Are New Drug Classes Gaining Momentum in the Acute Migraine Treatment Market?

New drug classes are gaining momentum in the acute migraine treatment market because they offer mechanisms of action specifically designed to target the biochemical processes involved in migraine attacks. One of the most important breakthroughs in recent years has been the development of CGRP (calcitonin gene-related peptide) receptor antagonists, known as gepants. CGRP is a neuropeptide believed to play a pivotal role in migraine pathogenesis by promoting inflammation and vasodilation in cerebral blood vessels. Gepants such as ubrogepant and rimegepant have been approved in several countries and offer a non-vasoconstrictive option that is safe for individuals with cardiovascular risk factors. Similarly, ditans like lasmiditan work on serotonin 5-HT1F receptors to inhibit migraine-related pain signaling without causing blood vessel constriction, addressing an important gap left by triptans. These novel therapies are appealing to clinicians because they provide acute relief while avoiding the limitations associated with older treatments, including delayed onset of action, drug overuse headaches, and contraindications in vulnerable populations. Furthermore, advancements in drug delivery systems are improving bioavailability and patient adherence. Formulations such as intranasal sprays and oral dissolvable tablets allow for faster absorption and easier administration during an active migraine, when swallowing pills may be difficult. Clinical trials have also shown these newer treatments to be well tolerated, with fewer gastrointestinal side effects and lower risks of medication overuse. With regulatory approvals expanding and real-world data supporting their safety and efficacy, these new classes are reshaping how acute migraines are managed and prompting a reevaluation of treatment guidelines across the globe.

What Are the Key Considerations for Clinicians in Tailoring Acute Migraine Therapy to Individual Patients?

Clinicians managing acute migraine treatment must balance efficacy, tolerability, comorbidities, and patient preferences when tailoring therapy, making personalized care increasingly important in this space. One of the most critical considerations is the patient’s cardiovascular health, as traditional triptans are contraindicated in individuals with a history of stroke, heart disease, or uncontrolled hypertension due to their vasoconstrictive effects. For these patients, newer options like gepants and ditans offer safer alternatives. Another factor is the frequency and intensity of migraine attacks. Patients with infrequent attacks may respond well to NSAIDs or triptans, while those with more frequent or treatment-resistant migraines may require access to next-generation medications or combination therapies. Clinicians must also consider the timing of treatment initiation, as early intervention during the mild phase of a migraine is typically more effective than delayed treatment after pain has escalated. The mode of drug administration is another vital consideration. Some patients prefer oral tablets for convenience, while others may require non-oral options such as nasal sprays or injectables if nausea or vomiting accompanies their attacks. Side effect profiles, potential drug-drug interactions, and ease of use all factor into adherence and overall patient satisfaction. Additionally, understanding a patient's prior treatment history and any history of medication overuse headaches is essential to avoid compounding the condition. With the increasing availability of diverse treatment options, clinicians are now better equipped to design individualized strategies that optimize outcomes and enhance the patient experience. As shared decision-making becomes a standard of care, involving patients in choosing their treatment options is critical for long-term success in managing acute migraine attacks.

What Forces Are Driving Growth in the Global Acute Migraine Treatment Market?

The global growth of the acute migraine treatment market is being driven by a combination of epidemiological, technological, regulatory, and consumer-focused factors that are reshaping the approach to migraine care. First and foremost, the high prevalence of migraines worldwide, affecting an estimated one billion people, has established a vast and underserved patient base that continues to seek better and faster relief from symptoms. As awareness of migraine as a serious and disabling neurological condition grows, healthcare systems are investing more resources into diagnosis and treatment. The expansion of health insurance coverage in many countries and the increasing inclusion of migraine therapies in national formularies are also improving patient access to both traditional and innovative medications. On the technology front, pharmaceutical companies are leveraging advances in molecular biology and neuroscience to develop more precise drugs that target the specific pathways involved in migraine attacks, such as CGRP and serotonin subtypes. Regulatory agencies like the FDA and EMA are responding to the unmet needs of migraine patients by expediting approvals through mechanisms like fast-track and breakthrough designations. This has shortened development timelines and brought new therapies to market more quickly. Patient demand for treatments with fewer side effects, rapid onset of action, and broader safety profiles is influencing pharmaceutical R&D priorities and driving product differentiation. Moreover, the growth of digital health platforms and migraine tracking apps is enabling better data collection and disease management, fostering more personalized and responsive treatment approaches. Education efforts by patient advocacy groups and professional societies are also raising standards of care globally. Collectively, these forces are not only fueling the expansion of the acute migraine treatment market but also paving the way for a future where migraine care is more accessible, effective, and aligned with individual patient needs.

SCOPE OF STUDY:

The report analyzes the Acute Migraine Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug, Other Drug Types); Administration Route (Oral Administration, Injection Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Agenus Inc.
• Amgen Inc.
• AstraZeneca plc
• Biohaven Ltd.
• CoLucid Pharmaceuticals Inc.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Endo International plc
• GlaxoSmithKline plc (GSK)
• H. Lundbeck A/S
• Impel Pharmaceuticals Inc.
• Johnson & Johnson (Janssen)
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries
• Tonix Pharmaceuticals
• Zosano Pharma Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Acute Migraine Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Migraine Throws the Spotlight on the Expanding Acute Migraine Treatment Market
  • Increased Awareness and Diagnosis Rates Propel Growth in Demand for Fast-Acting Therapeutic Options
  • Advancements in CGRP Receptor Antagonists and Ditans Drive Adoption of Targeted Non-Triptan Therapies
  • Shift Away from Opioid-Based Pain Management Strengthens Business Case for Safer, Migraine-Specific Medications
  • Here's the Story: Neurologists and Primary Care Providers Turning to New Drug Classes for Refractory Migraine Cases
  • Rise of Digital Health Tools and Telemedicine Accelerates Access to Acute Migraine Medications and Management Plans
  • Growing Use of Self-Injectable Devices and Orally Disintegrating Tablets Enhances Patient Compliance and Convenience
  • Expansion of Over-the-Counter (OTC) Options and Combination Formulations Spurs Consumer-Driven Market Growth
  • Pharmaceutical Innovation in Nasal Sprays and Inhalable Delivery Systems Sustains Focus on Rapid-Onset Relief
  • Chronic Migraine Sufferers Driving Dual Use of Preventive and Acute Therapies Boost Market Potential
  • Rising Demand for Non-Invasive Neuromodulation Devices Opens New Avenues for Acute Migraine Relief
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Acute Migraine Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Acute Migraine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Triptans Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Triptans Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Triptans Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for CGRP Antagonist Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for CGRP Antagonist Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for CGRP Antagonist Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for NSAID Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for NSAID Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for NSAID Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blockers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Beta-Adrenergic Blockers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Beta-Adrenergic Blockers Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Ergot Alkaloids Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Ergot Alkaloids Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Ergot Alkaloids Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Injection Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• JAPAN
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• CHINA
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• EUROPE
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Acute Migraine Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• FRANCE
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• GERMANY
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Acute Migraine Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• INDIA
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Acute Migraine Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Acute Migraine Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• AFRICA
  • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION